These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2185606)

  • 1. Movement disorders and new azapirone anxiolytic drugs.
    Jann MW; Froemming JH; Borison RL
    J Am Board Fam Pract; 1990; 3(2):111-9. PubMed ID: 2185606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent movement disorders induced by buspirone.
    LeWitt PA; Walters A; Hening W; McHale D
    Mov Disord; 1993 Jul; 8(3):331-4. PubMed ID: 8101969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buspirone: what is it all about?
    Loane C; Politis M
    Brain Res; 2012 Jun; 1461():111-8. PubMed ID: 22608068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of buspirone's anxiolytic action.
    Tunnicliff G
    Pharmacol Toxicol; 1991 Sep; 69(3):149-56. PubMed ID: 1796057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notes on buspirone's mechanisms of action.
    Garattini S; Caccia S; Mennini T
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):19-24. PubMed ID: 6130069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Buspirone: a new non-benzodiazepine anxiolytic drug].
    Honorato J; Catalán M
    Rev Clin Esp; 1990 Apr; 186(6):286-91. PubMed ID: 2203117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone in the treatment of tardive dyskinesia.
    Ross CA
    Med Hypotheses; 1987 Mar; 22(3):321-8. PubMed ID: 2884555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone revisited.
    Lydiard RB
    J Clin Psychiatry; 1989 Aug; 50(8):308. PubMed ID: 2569458
    [No Abstract]   [Full Text] [Related]  

  • 9. Buspirone: chemical profile of a new class of anxioselective agents.
    Temple DL; Yevich JP; New JS
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):4-10. PubMed ID: 6185470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study.
    Ratey J; Sovner R; Parks A; Rogentine K
    J Clin Psychiatry; 1991 Apr; 52(4):159-62. PubMed ID: 2016248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azaspirodecanediones in generalized anxiety disorder: buspirone.
    Ortiz A; Pohl R; Gershon S
    J Affect Disord; 1987; 13(2):131-43. PubMed ID: 2960708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azapirones: an alternative to benzodiazepines for anxiety.
    Cadieux RJ
    Am Fam Physician; 1996 May; 53(7):2349-53. PubMed ID: 8638511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?
    Crow TJ; Cross AJ; Johnstone EC; Owen F; Owens DG; Waddington JL
    J Clin Psychopharmacol; 1982 Oct; 2(5):336-40. PubMed ID: 7130435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine.
    Jann MW
    Pharmacotherapy; 1991; 11(3):179-95. PubMed ID: 1677765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Garcia J; Winkler C; Björklund A; Carta M
    Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.